Regenxbio Stock News

Clinical-stage biotech, Regenxbio <> is trading sharply higher on Wednesday to record the biggest intraday gain since September after the company unveiled a new initiative…

Shares of Regenxbio (RGNX) are up 8% in after-hours trading despite the companys Q4 2021 earnings results that beat on both the top and bottom lines.

REGENXBIO's (RGNX) CEO Ken Mills on Q4 2021 Results - Earnings Call Transcript

Regenxbio press release (RGNX): Q4 GAAP EPS of $6.67 beats by $2.93.Revenue of $398.65M (+1758.5% Y/Y) beats by $142.89M.

ROCKVILLE, Md., March 1, 2022 /PRNewswire/ -- Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314 Received upfront payment of $370 million and eligible to receive up to $1.38 billion in additional development, regulatory and commercial milestones…

Regenxbio (RGNX) delivered earnings and revenue surprises of 55.84% and 29.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Regenxbio (NASDAQ:RGNX) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is $4.31 (+447.6% Y/Y) and the consensus…

ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral presentations on Clearside''s SCS injection platform featuring the SCS Microinjector ® were given at the Bascom Palmer Eye Institute''s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12, 2022. Clearside''s presentation, entitled, "The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians" described the preclinical and clinical data demonstrating the methodology and benefits of suprachoroidal delivery. The preclinical data in multiple animal models showed the potential advantages of SCS delivery over intravitreal delivery, the durability potential of small molecule suspensions, and the possible suitability of suprachoroidal delivery for gene therapy. In conjunction with partners, Clearside''s technology is currently being explored in five clinical trials in four indications: neovascular age-related macular degeneration (wet AMD), diabetic retinopathy, uveitic macular edema, and choroidal melanoma. "Suprachoroidal delivery via our SCS Microinjector offers clinicians several potential core benefits for treatment of their patients with back of the eye diseases: targeting of therapy to affected tissues; compartmentalization of therapy to avoid non-diseased tissues; higher bioavailability; and potential longer durability," said Thomas A.

Regenxbio Inc (NASDAQ: RGNX ) announced additional interim data from Cohorts 1-3 of Phase 1/2 trial of RGX-121 for patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), The data were shared at the 18th Annual WORLDSymposium. RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector. RGX-121 is reported to be well-tolerated … Full story available on Benzinga.com

Announcing initial data from its Phase I/II trial for RGX-111 in severe Mucopolysaccharidosis Type I (MPS I), REGENXBIO (RGNX) suggested there was systemic and CNS biomarker…

Regenxbio Inc RGNX announced additional interim data from Cohorts 1-3 of Phase 1/2 trial of RGX-121 for patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II),  Get the I

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on…

ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday,

Regenxbio Inc (RGNX) shares closed 0.7% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 17.6% year-to-date, down 44.7% over the past 12 months, and up 43.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 50.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3151.1% The company's stock price performance over the past 12 months lags the peer average by 179.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.